PedAM
Pediatric Disease Annotations & Medicines
| Disease | myocardial infarction |
| Phenotype | C0011860|type 2 diabetes |
| Sentences | 45 |
| PubMedID- 24223556 | For another example, consider the question: “what is the relationship between adherence to metformin (as measured by hemoglobin a1c < 6) and incidence of myocardial infarction in patients with type 2 diabetes?” the following key questions arise: how much adherence? |
| PubMedID- 23226370 | Although clinical outcomes of acute myocardial infarction (ami) in patients with type 2 diabetes mellitus (t2dm) is well established to be worse than non-diabetic patients [1], [2], the reasons for this remain unclear. |
| PubMedID- 20431807 | Materials and methods: 30 type 2 diabetes mellitus cases with myocardial infarction and equal members of type 2 diabetics without complications are enrolled. |
| PubMedID- 25078899 | Low adiponectin levels and increased risk of type 2 diabetes in patients with myocardial infarction. |
| PubMedID- 21188086 | The aim of this study is to examine the circadian rhythms of acute myocardial infarction in patients with type 2 diabetes. |
| PubMedID- 25663871 | The united kingdom prospective diabetes study (9) demonstrated that metformin significantly reduced the risk of myocardial infarction by 39% in patients with type 2 diabetes. |
| PubMedID- 21357366 | In addition, another recent prospective study conducted in spain found a hazard ratio of 0.33 for fatal or nonfatal myocardial infarction in individuals with type 2 diabetes compared with nondiabetic individuals with a prior myocardial infarction (11). |
| PubMedID- 21736547 | Furthermore, meta-analysis of seven long-term studies suggested that acarbose reduced the risk of myocardial infarction for patients with type 2 diabetes [137]. |
| PubMedID- 26279482 | Comparison of basal insulin therapies with regard to the risk of acute myocardial infarction in patients with type 2 diabetes: an observational cohort study. |
| PubMedID- 20484611 | Recent meta-analyses suggest an increased risk of acute myocardial infarction (ami) in patients with type 2 diabetes mellitus (t2dm) treated with rosiglitazone. |
| PubMedID- 20682359 | Sudden cardiac death after myocardial infarction in patients with type 2 diabetes. |
| PubMedID- 26543616 | We present one such unique case of a patient with an asymptomatic myocardial infarction complicated by vsr, type 2 diabetes mellitus and chronic bronchitis. |
| PubMedID- 23184042 | The a1/a2 polymorphism of the glycoprotein iiia gene and myocardial infarction in caucasians with type 2 diabetes. |
| PubMedID- 25834461 | Dpp-4 inhibitors are thought to reduce the risk of cardiovascular events, particularly myocardial infarction, in patients with type 2 diabetes.32 recently, ervinna et al33 reported that the administration of anagliptin attenuates atherosclerosis secondary to suppression of the proliferation of vascular smooth muscles and monocyte inflammatory reactions in apo-e–deficient mice, an animal model of progressive atherosclerosis. |
| PubMedID- 22802849 | At the same time, in the diabetic group, absence of coronary artery calcifications is associated with low short-term risk of death and cs index may be a useful tool in risk assessment of occurrence of silent myocardial infarction in patients with stable, uncomplicated type 2 diabetes [13,14]. |
| PubMedID- 23998120 | The results published so far have considered the effect of the relationships of polymorphisms in the promoter region of the basic fibroblast growth factor gene with proliferative diabetic retinopathy [16] or myocardial infarction [15] in patients with type 2 diabetes. |
| PubMedID- 24229770 | Although pioglitazone significantly prevented the progression of coronary atherosclerosis and reduced the recurrence of myocardial infarction in patients with type 2 diabetes mellitus (dm), it remains unclear whether pioglitazone could attenuate coronary artery inflammation. |
| PubMedID- 24773097 | Incremental costs associated with myocardial infarction and stroke in patients with type 2 diabetes mellitus: an overview for economic modeling. |
| PubMedID- 21907990 | We investigated whether snp rs4788102, which captures the entire sh2b1 variability, is associated with coronary artery disease (cad) and/or myocardial infarction (mi) in patients with type 2 diabetes mellitus (t2dm). |
| PubMedID- 22858312 | Association of manganese superoxide dismutase and glutathione s-transferases genotypes with myocardial infarction in patients with type 2 diabetes mellitus. |
| PubMedID- 22439599 | Reported that bezafibrate significantly decreased the combined incidence of ischemic change in ecg and documented myocardial infarction in patients with type 2 diabetes [37]. |
| PubMedID- 24660315 | Objective: to evaluate if patient characteristics would have significant effects on outcomes for inpatients' myocardial infarction (mi) with type 2 diabetes (t2d) admitted to non-federal hospitals. |
| PubMedID- 22545680 | Better glycaemic control) was associated with a reduced risk of clinically evident microvascular complications and a nonsignificant reduction in the relative risk of myocardial infarction in patients with newly diagnosed type 2 diabetes mellitus [17]. |
| PubMedID- 24595635 | Increased risk of subsequent myocardial infarction in patients with type 2 diabetes: a retrospective cohort study using the u.k. |
| PubMedID- 26410961 | The study included patients suffering myocardial infarction with and without type 2 diabetes mellitus. |
| PubMedID- 22855732 | However, this is the first study to demonstrate that the beneficial effects of bariatric surgery on cardiovascular risk factors are also followed by reduced risk of myocardial infarction in individuals with type 2 diabetes. |
| PubMedID- 21576196 | An increased incidence of myocardial infarction with rosiglitazone in patients with type 2 diabetes mellitus (t2dm) has been reported. |
| PubMedID- 24742256 | Furthermore, the diabetes intervention study and the san luigi gonzaga study investigators have reported specific associations between postprandial glucose concentrations and risk for subsequent cv events, such as myocardial infarction, in patients with type 2 diabetes [85,86]. |
| PubMedID- 20465096 | The risk of myocardial infarction in patients with type 2 diabetes is 3-5 times higher than in non-diabetics. |
| PubMedID- 20157205 | It was found that 178 (52.4%) patients with type 2 diabetes had law risk of development of myocardial infarction, 89 (26.2%) patients - moderate and 73 patients (21.4%) - the high risk of myocardial infarction. |
| PubMedID- 24124429 | [3] notably, the risk of myocardial infarction (mi) in patients with type 2 diabetes with no previous history of coronary heart disease is similar to that among patients without diabetes who have already had mi. |
| PubMedID- 24708579 | Pioglitazone also reduced the risk of hospitalization for acute myocardial infarction in patients with type 2 diabetes in comparison with rosiglitazone [16,17]. |
| PubMedID- 24089535 | St-segment elevation myocardial infarction in women with type 2 diabetes. |
| PubMedID- 22679279 | Relationship between angiotensin-converting enzyme gene insertion/deletion polymorphism, angiographically defined coronary artery disease and myocardial infarction in patients with type 2 diabetes mellitus. |
| PubMedID- 24619127 | myocardial infarction) in persons with type 2 diabetes who are exposed to air pollution [5], [15]. |
| PubMedID- 21709632 | Importantly, cardiovascular outcome studies further suggested that pioglitazone reduced all-cause mortality, myocardial infarction, and stroke in patients with type 2 diabetes [24,48]. |
| PubMedID- 20478050 | More data are required not only for efficacy, but also to address the long-term safety of rosiglitazone in these patients, particularly in light of the recent report that rosiglitazone is associated with a significant increase in the risk of myocardial infarction in patients with type 2 diabetes mellitus [55]. |
| PubMedID- 25771308 | Modeling of in hospital mortality determinants in myocardial infarction patients, with and without type 2 diabetes, undergoing pharmaco-invasive strategy: the first national report using two approaches in iran. |
| PubMedID- 24529823 | Glycemic variability predicts cardiovascular complications in acute myocardial infarction patients with type 2 diabetes mellitus. |
| PubMedID- 21444887 | Background: in the bypass angioplasty revascularization investigation 2 diabetes (bari 2d) trial, an initial strategy of coronary revascularization and optimal medical treatment (rev) compared with an initial optimal medical treatment with the option of subsequent revascularization (med) did not reduce all-cause mortality or the composite of cardiovascular death, myocardial infarction, and stroke in patients with type 2 diabetes mellitus and stable ischemic heart disease. |
| PubMedID- 23286208 | Furthermore, short- and long-term survival following a myocardial infarction is lower in patients with type 2 diabetes mellitus compared to those without[4-8]. |
| PubMedID- 22397700 | Early initiation of antihyperglycaemic medication is associated with reductions in microvascular events and long-term, legacy effects with reductions in myocardial infarction and death in patients with newly diagnosed type 2 diabetes [9-11]. |
| PubMedID- 26209521 | Low concentrations of serum testosterone predict acute myocardial infarction in men with type 2 diabetes mellitus. |
| PubMedID- 20158090 | Thus, pioglitazone reduced the composite of all-cause mortality, non-fatal myocardial infarction, and stroke in patients with type 2 diabetes who have a high risk of macrovascular events. |
| PubMedID- 25887378 | An informed shared decision making programme on the prevention of myocardial infarction for patients with type 2 diabetes in primary care: protocol of a cluster randomised, controlled trial. |
Page: 1